Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 12/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.50 |
| ▸ | OXTR | P30559 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12406996 | 0.89 | MEN1 (0.57) | PTGER1MEN1LMNAKMT2AOXTR | |
| SCHEMBL12407000 | 0.84 | MEN1 (0.54) | PTGER1MEN1LMNAKMT2AOXTR | |
| SCHEMBL12481950 | 0.83 | ESR1 (0.62) | PTGER1MEN1LMNAKMT2AESR1 | |
| SCHEMBL2176662 | 0.81 | PTGER1 (0.52) | PTGER1MEN1LMNAKMT2AMCOLN3 | |
| SCHEMBL13894165 | 0.81 | PTGER1 (0.52) | PTGER1MEN1LMNAKMT2AMCOLN3 | |
| SCHEMBL12407173 | 0.81 | PTGER1 (0.58) | PTGER1MEN1KMT2AOXTR | |
| SCHEMBL2176077 | 0.81 | KEAP1 (0.64) | PTGER1MEN1LMNAKMT2AOXTR | |
| SCHEMBL12407191 | 0.80 | HPGD (0.57) | PTGER1MEN1LMNAKMT2AOXTR | |
| SCHEMBL27874897 | 0.80 | ESR1 (0.45) | PTGER1MEN1LMNAKMT2AMCOLN3 | |
| SCHEMBL12481491 | 0.79 | PTGER1 (0.56) | PTGER1MEN1LMNAKMT2AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050446-B1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-2050446-B1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2050446-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-2050446-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | PTGER1 1/4885MEN1 3347/4885LMNA 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.